Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. Source
No articles found.
Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the...
Intuitive Surgical, Inc. (Nasdaq:ISRG), headqua...
crooru is an on-demand, location-based app that connects health care staff and nur...
crooru is an on-demand, location-based app that...
Addus HomeCare is a comprehensive provider of home and community based services, w...
Addus HomeCare is a comprehensive provider of h...
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...
RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Join the National Investor Network and get the latest information with your interests in mind.